A multinational study identified immune resilience as a critical factor influencing life span, HIV/AIDS, flu, sepsis mortality, recurrent skin cancer, and COVID-19 mortality. Individuals with optimal levels of immune resilience were more likely to resist infections and recover from inflammatory stressors.
Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.
Previous antibody responses to harmless coronaviruses contribute to SARS-CoV-2 immunity, reducing infection severity and hospitalization rates. Researchers found that people with strong immune responses to other human coronaviruses have some protection against SARS-CoV-2 infection.